Please check your internet connection and try again.
# Bricanyl (Terbutaline)
## Overview
Terbutaline is a selective beta-2 adrenergic receptor agonist. It acts as a bronchodilator by stimulating adenyl cyclase to increase cyclic AMP (cAMP) levels in bronchial smooth muscle cells, leading to relaxation.
## Primary Indications
* **Asthma/COPD:** Treatment of reversible bronchospasm.
* **Obstetrics (Off-label/Historical):** Management of preterm labor (FDA has issued a black box warning against long-term use >48-72 hours due to serious maternal cardiac adverse events).
## Adult Dosing
* **Bronchospasm (Inhaled/Aerosol/Nebulizer):** 5 mg via nebulizer or 2 inhalations (0.4–0.5 mg) via MDI every 4–6 hours as needed.
* **Bronchospasm (Subcutaneous):** 0.25 mg injected into the lateral deltoid area. May repeat once after 15–30 minutes if necessary. Do not exceed 0.5 mg in a 4-hour period.
## Pediatric Dosing
* **Bronchospasm (Children >12 years):** Same as adult dosing.
* **Bronchospasm (Children <12 years):** Not generally recommended due to lack of established safety/efficacy data for standard delivery systems. If used based on local institutional protocol, nebulized dosing is typically 0.05–0.15 mg/kg per dose every 4–6 hours (Max 5 mg/dose).
## Dose Adjustments
* **Renal Impairment:** Use with caution. Terbutaline is renally excreted; dosing intervals may need to be extended in severe impairment.
* **Hepatic Impairment:** No specific guidelines; use caution.
## Contraindications
* Known hypersensitivity to terbutaline or any component of the formulation.
* **Oral formulations:** Generally discouraged due to systemic side effects vs. efficacy ratio.
## Adverse Effects
* **Cardiovascular:** Tachycardia, palpitations, arrhythmias, hypertension, or hypotension.
* **Neurologic:** Tremor (common, dose-dependent), nervousness, dizziness, headache.
* **Metabolic:** Hypokalemia (with high/frequent doses), hyperglycemia.
## Key Drug Interactions
* **Beta-blockers:** May antagonize the therapeutic effects and potentially induce bronchospasm.
* **Diuretics:** Non-potassium sparing diuretics may exacerbate terbutaline-induced hypokalemia.
* **MAO Inhibitors/TCAs:** May potentiate the effect of terbutaline on the vascular system.
## Monitoring
* **Cardiac:** Pulse, blood pressure, and ECG (if history of cardiac disease or high/frequent doses).
* **Respiratory:** Monitor for effectiveness (reduction in wheezing, improved breath sounds, improved peak flow).
* **Electrolytes:** Serum potassium levels in patients on high-dose or frequent therapy.
## Clinical Pearls
* **Systemic vs. Inhaled:** Inhaled delivery is preferred for bronchospasm to maximize local effect and minimize systemic adverse effects, particularly tachycardia and tremor.
* **Tolerance:** Regular/chronic use may lead to reduced sensitivity (tolerance) to the drug’s bronchodilator effects.
* **Pregnancy Warning:** Use for preterm labor is strictly restricted due to risks of maternal pulmonary edema and cardiac ischemia.
***
**Disclaimer:** This information is for educational purposes only. Drug dosing, contraindications, and clinical protocols may vary by institution and patient-specific factors. Always verify current prescribing information and local hospital guidelines before administering medication.
